Snack Manufacturing Business Assets for Sale in New York, United States
Ownership Duration | 10-20 year(s) |
Industries | Snack Manufacturing |
Locations | New York |
Local Time | 8:57 PM America / New York |
Listed By | Advisor / Business Broker |
Status | Active |
Globally patented & branded chewing gum that effectively removes all pre-cancerous residual components and traces of tobacco, alcohol, marijuana and other toxic chemicals left behind in the oral cavity after consumption.
This Is the Sale of a Globally Patented & Branded Chewing Gum That Has Lead to a Scientific Breakthrough in the Cancer Space Preventing Oral and Upper Digestive Cancers, Including Viral Transfers.
University Tested, Branded Chewing Gum, Wafer, and Medicinal Powder That Effectively Removes up to 100% of Precancerous and Other Toxic Chemicals Including the Residual Traces of Tobacco, Alcohol, and Marijuana Left Behind in the Oral Cavity After Their Consumption.
Recently Conducted Clinical Trials Prove This Products Effectiveness and It's Limitless Possibilities.
1) Oral Hygiene.
2) HPV.
3) Root Canal Residue extraction:
4) Tobacco.
5) Cellular protectant for precancerous oral genomes.
6) Precancerous post alcohol breakdown residue.
7) Alcohol residue remover for worldwide Breath testing devices.
8) Chronic Halitosis.
9) Binding agent for Viral and Bacterial Transfer.
Foundational University Study:
It is a well known fact that carcinogens and other residual chemical components left behind in the oral cavity after smoking or chewing tobacco causes many different types of cancers both in the mouth and other parts of the body.
This patented gum is manufactured utilizing a special proprietary cold press technology that allows the gum to absorb these carcinogens within the oral cavity after which you simply throw the gum away.
Medicinal Delivery:
In addition, a global patent was also recently issued for this gum as a disposable oral cavity pharmaceutical delivery device. Oral delivery allows more direct vascular access to the brain, cardiac, renal and pulmonary systems.
Phase II Study:
Future clinical studies are in development to determine therapeutic oral delivery of phosphorus binding supplement to prevent abnormal bone calcium loss in chronic kidney disease stage iii and iv patients. A significant percentage of ckd patients are due to diabetes.